{"id":"https://openalex.org/W2584119965","doi":"https://doi.org/10.1182/blood.v126.23.4575.4575","title":"Pharmacokinetics and Pharmacodynamics after Subcutaneous Dosing of the iNKT Cell Depleting Antibody NKTT120","display_name":"Pharmacokinetics and Pharmacodynamics after Subcutaneous Dosing of the iNKT Cell Depleting Antibody NKTT120","publication_year":2015,"publication_date":"2015-12-03","ids":{"openalex":"https://openalex.org/W2584119965","doi":"https://doi.org/10.1182/blood.v126.23.4575.4575","mag":"2584119965"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v126.23.4575.4575","doi":"https://doi.org/10.1182/blood.v126.23.4575.4575","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.4575.4575","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020230031","display_name":"Robert G. Schaub","orcid":"https://orcid.org/0000-0003-2085-5914","observed_orcids":["https://orcid.org/0000-0003-2085-5914"]},"institutions":[{"id":"https://openalex.org/I4210130256","display_name":"NKT Therapeutics (United States)","ror":"https://ror.org/040wa6e75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Schaub","raw_affiliation_strings":["NKT Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NKT Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4210130256"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039261127","display_name":"Abraham Thariath","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130256","display_name":"NKT Therapeutics (United States)","ror":"https://ror.org/040wa6e75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abraham Thariath","raw_affiliation_strings":["NKT Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NKT Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4210130256"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040627601","display_name":"Felix Scheuplein","orcid":"https://orcid.org/0000-0002-2691-0796","observed_orcids":["https://orcid.org/0000-0002-2691-0796"]},"institutions":[{"id":"https://openalex.org/I4210130256","display_name":"NKT Therapeutics (United States)","ror":"https://ror.org/040wa6e75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Felix Scheuplein","raw_affiliation_strings":["NKT Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NKT Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4210130256"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083889976","display_name":"Robert D. Mashal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130256","display_name":"NKT Therapeutics (United States)","ror":"https://ror.org/040wa6e75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Mashal","raw_affiliation_strings":["NKT Therapeutics, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NKT Therapeutics, Waltham, MA","institution_ids":["https://openalex.org/I4210130256"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210130256"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.33566076,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"126","issue":"23","first_page":"4575","last_page":"4575"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.6064000129699707,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.6064000129699707,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.1695999950170517,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.03480000048875809,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8209999799728394},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9309999942779541},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9670000076293945},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.8479999899864197},{"id":"https://openalex.org/keywords/cynomolgus-monkeys","display_name":"Macaca fascicularis","score":0.859000027179718},{"id":"https://openalex.org/keywords/sickle-cell-disease","display_name":"sickle cell disease","score":0.9440000057220459},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.7300000190734863},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.7710000276565552},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6330000162124634},{"id":"https://openalex.org/keywords/half-life","display_name":"half-life","score":0.7519999742507935},{"id":"https://openalex.org/keywords/time-to-recovery","display_name":"time to recovery","score":0.5109999775886536},{"id":"https://openalex.org/keywords/intravenous-comparison","display_name":"intravenous comparison","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6796571016311646},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5993672013282776},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5767819881439209},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5363854765892029},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5225560069084167},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.5204789638519287},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5140637159347534},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5121669769287109},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.49067890644073486},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4461532235145569},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.42285650968551636}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v126.23.4575.4575","doi":"https://doi.org/10.1182/blood.v126.23.4575.4575","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.4575.4575","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2584418414","https://openalex.org/W2588948985","https://openalex.org/W223872111","https://openalex.org/W2556566801","https://openalex.org/W2289512502","https://openalex.org/W2000643138","https://openalex.org/W2583491977","https://openalex.org/W2597345362","https://openalex.org/W7096962111","https://openalex.org/W976022473"],"abstract_inverted_index":{"Abstract":[0],"The":[1,144,232,252,327,355],"iNKT":[2,32,42,70,99,199,223,238,261,330],"cell":[3,13,26,61,200,331],"(invariant":[4],"Natural":[5],"Killer":[6],"T":[7,60],"cell)":[8],"is":[9,51,380],"a":[10,52,80,137,173,186,358,374],"unique":[11,59],"immune":[12],"that":[14,67,87,89,346,366],"has":[15],"been":[16],"shown":[17],"to":[18,30,37,57,119,126,136,150,162,254,289,335,345,403],"be":[19,36,120,133,371],"associated":[20],"with":[21,95,259,267,275,287],"chronic":[22,138],"inflammation":[23,34],"in":[24,44,82,93,105,218,228,241,386],"sickle":[25],"disease.":[27],"One":[28],"approach":[29],"reducing":[31],"mediated":[33],"would":[35,132],"reduce":[38],"the":[39,45,58,106,124,152,155,245,268,276,313,323,338,349,383],"number":[40],"of":[41,47,63,109,146,157,177,191,202,221,234,293,300,329],"cells":[43,66,71,100,224,239,262],"tissue":[46],"SCD":[48,96,387],"patients.":[49],"NKTT120":[50,158,171,209,283,301,363,397],"humanized":[53],"monoclonal":[54],"antibody":[55,73],"directed":[56],"receptor":[62],"invariant":[64],"NKT":[65,416],"can":[68],"deplete":[69],"by":[72,129,205,213,382],"dependent":[74,258],"cellular":[75],"cytotoxicity.":[76],"It":[77],"recently":[78],"completed":[79],"first":[81],"man":[83],"Phase":[84],"1":[85],"study":[86,148],"demonstrated":[88],"intravenous":[90,115,188,376],"single":[91,174,187],"doses":[92,216,402],"adults":[94],"specifically":[97],"reduced":[98],"without":[101,225],"dose":[102,127,176,190,257,271,285,315,325,342,353,377],"limiting":[103],"toxicity":[104],"therapeutic":[107,375],"range":[108],"0.3":[110,180,192,277,339,350],"and":[111,122,141,154,208,272,280,307,317,333,364],"1.0":[112],"mg/kg.":[113],"Although":[114],"dosing":[116,304,360],"was":[117,149,211,248,256,284,305,309,343],"found":[118,263],"effective":[121],"safe,":[123],"ability":[125],"patients":[128,388],"subcutaneous":[130,175,384],"administration":[131],"an":[134],"asset":[135],"treatment":[139],"strategy":[140,361],"patient":[142],"compliance.":[143],"purpose":[145],"this":[147],"assess":[151],"bioavailability":[153],"efficacy":[156],"administered":[159,170,381],"subcutaneously":[160],"(SC)":[161],"cynomolgus":[163,167],"monkeys.":[164],"Female":[165],"adult":[166],"monkeys":[168],"were":[169,196],"as":[172,185],"0.03,":[178],"0.1,":[179],"mg/kg":[181,193,270,278,340,351],"(n=3":[182],"each)":[183],"or":[184,400],"(IV)":[189],"(n=3).":[194],"Animals":[195],"monitored":[197,212],"for":[198,312,322,337,348,362,396],"depletion":[201,220,332],"peripheral":[203,236],"blood":[204,222,230,237],"FACS":[206],"analysis":[207],"concentration":[210,247,292],"ELISA.":[214],"All":[215],"resulted":[217],"complete":[219],"any":[226],"change":[227],"other":[229],"cells.":[231],"return":[233],"measureable":[235,260],"occurred":[240],"each":[242],"group":[243,316],"when":[244,373],"plasma":[246,291],"\u2264":[249],"100":[250],"ng/mL.":[251],"time":[253,288,334],"recovery":[255,336],"at":[264],"4-6":[265],"weeks":[266,274],"0.03":[269],"8-14":[273],"IV":[279,314,352,399],"SC":[281,297,303,324,341,359,401],"doses.":[282],"proportional":[286],"maximum":[290],"48":[294],"hours":[295],"following":[296],"dosing.":[298],"Bioavailability":[299],"after":[302],"~60%":[306],"T1/2":[308],"15":[310],"days":[311,321],"ranged":[318],"from":[319],"11-19":[320],"groups.":[326],"duration":[328],"similar":[344,367],"observed":[347],"group.":[354],"results":[356],"support":[357],"suggest":[365],"pharmacodynamic":[368],"responses":[369],"could":[370],"expected":[372],"(0.3":[378],"mg/kg)":[379],"route":[385],"every":[389],"3-4":[390],"months.":[391],"Plasma":[392],"Concentration":[393],"vs.":[394],"Time":[395],"Following":[398],"Cynomolgus":[404],"Monkeys":[405],"Figure":[406,408,410,412],"1.":[407,409],"2.":[411,413],"Disclosures":[414],"Schaub:":[415],"Therapeutics:":[417,422,427,431],"Employment,":[418,423,432],"Equity":[419,424,428,433],"Ownership.":[420,425,429,434],"Thariath:NKT":[421],"Scheuplein:NKT":[426],"Mashal:NKT":[430]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-10T00:00:00"}